• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors

    10/24/22 9:00:00 AM ET
    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto & Home Supply Stores
    Consumer Discretionary
    Get the next $ELAN alert in real time by email

    TCW Special Purpose Acquisition Corp. (NYSE:TSPQ), a $464 million blank check company sponsored by The TCW Group, Inc. ("TCW"), announced that it has appointed Nanxi Liu to the Company's Board of Directors.

    Since April 2021, Ms. Liu has served on the TCW Special Purpose Acquisition Corporation's Advisory Board. She is the Co-Founder and Co-CEO of Blaze Technology, a no-code platform that enables teams to build web applications and internal tools. Ms. Liu co-founded and served as CEO of Enplug, a leading digital signage software company used by Fortune 500 companies, until it was acquired in 2021. She previously co-founded Nanoly Bioscience, a venture-backed biotech company that develops polymers that eliminate the need of refrigeration for vaccines and therapeutics.

    Ms. Liu serves on the Board of Directors of CarParts.com (NASDAQ:PRTS), a leading online provider of automotive parts and accessories, and served on the Board of Directors of Kindred Biosciences (NASDAQ:KIN), a leading biopharmaceutical company for pets, until it was acquired by Elanco Animal Health (NYSE:ELAN). She serves on the Board of Advisors for Covington Capital Management and is a Partner at XFactor Ventures, a leading investor in women-founded startups. Ms. Liu was named one of Forbes 30 Under 30 (in 2016) and Fortune's 10 Most Promising Women Entrepreneurs (in 2015).

    "For the past 18 months, we have benefited from Nanxi's advice and guidance as a member of our Advisory Board, and we are pleased to now welcome her as a new member of the Board of Directors," said Joseph R. Shaposhnik, TCW Special Purpose Acquisition Corp. Chairman and CEO. "She is a highly successful technology entrepreneur and brings a unique perspective to the leaders of businesses and our impressive team of advisors and directors."

    TCW Special Purpose Acquisition Corp. intends to identify, merge with and take public a durable and predictable business well positioned to deliver superior revenue growth. Its management is associated with TCW's New America Premier business unit, which was established by Mr. Shaposhnik in 2015.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities.

    About TCW Special Purpose Acquisition Corp.

    TCW Special Purpose Acquisition Corp. (the "Company"), a Delaware corporation, is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with a private company. The Company is sponsored by The TCW Group, Inc., a leading global investment management firm with approximately $220 billion of assets under management. For more information please visit www.tcwspac.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20221024005377/en/

    Get the next $ELAN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELAN
    $PRTS
    $TSPQ
    $KIN

    CompanyDatePrice TargetRatingAnalyst
    Elanco Animal Health Incorporated
    $ELAN
    1/22/2026Neutral → Overweight
    Piper Sandler
    Elanco Animal Health Incorporated
    $ELAN
    12/9/2025$30.00Overweight
    Barclays
    Elanco Animal Health Incorporated
    $ELAN
    11/21/2025$27.00Overweight
    KeyBanc Capital Markets
    Elanco Animal Health Incorporated
    $ELAN
    11/19/2025$25.00Hold → Buy
    Argus
    Elanco Animal Health Incorporated
    $ELAN
    10/7/2025$24.00Neutral → Overweight
    Analyst
    Elanco Animal Health Incorporated
    $ELAN
    7/17/2025$18.00Market Perform → Outperform
    Leerink Partners
    Elanco Animal Health Incorporated
    $ELAN
    6/26/2025Mkt Perform → Outperform
    William Blair
    CarParts.com Inc.
    $PRTS
    3/6/2025$3.00Hold → Buy
    Craig Hallum
    More analyst ratings

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    SEC Filings

    View All

    SEC Form 10-K filed by CarParts.com Inc.

    10-K - CarParts.com, Inc. (0001378950) (Filer)

    3/5/26 5:16:50 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    CarParts.com Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CarParts.com, Inc. (0001378950) (Filer)

    3/5/26 4:04:14 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    SEC Form 10-K filed by Elanco Animal Health Incorporated

    10-K - Elanco Animal Health Inc (0001739104) (Filer)

    2/24/26 9:19:48 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Modi Rajeev A. covered exercise/tax liability with 4,392 shares, decreasing direct ownership by 3% to 155,901 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/5/26 4:21:53 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    GC AND CORP SEC O'Neill Shiv covered exercise/tax liability with 4,738 shares, decreasing direct ownership by 5% to 83,834 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/5/26 4:19:14 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N covered exercise/tax liability with 37,898 units of Common Stock, decreasing direct ownership by 2% to 2,051,898 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    3/5/26 4:17:34 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CarParts.com Reports Fourth Quarter and Fiscal Year 2025 Results

    LOS ANGELES, March 5, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the fourth quarter and fiscal year ended January 3, 2026.  Fiscal Year 2025 (53 weeks) Summary vs. Fiscal Year 2024 (52 weeks)Closed $35.7 million strategic investment from A-Premium, ZongTeng Group, and CDH Investments.Net sales decreased 7% to $547.5 million.Gross profit of $179.3 million vs. $196.7 million, with gross margin of 32.8%.Net loss w

    3/5/26 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco to Participate in Upcoming Investor Conferences

    INDIANAPOLIS, Ind., Feb. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that management will participate in upcoming investor conferences. On Thursday, February 26, Jeff Simmons, president and CEO, and Bob VanHimbergen, executive vice president and CFO, will participate in a fireside chat at the BofA 2026 Animal Health Summit at 11:35 a.m. ET.On Monday, March 2, Bob VanHimbergen, executive vice president and CFO, and Luke Smith, vice president and CFO – US Pet Health, US Farm Animal, and Global Manufacturing, will participate in a fireside

    2/19/26 8:00:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kurzius Lawrence Erik bought $213,000 worth of shares (10,000 units at $21.30), increasing direct ownership by 8% to 131,773 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/16/25 4:42:47 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N bought $478,496 worth of shares (22,000 units at $21.75) (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:41:24 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Modi Rajeev A. bought $95,985 worth of shares (4,500 units at $21.33), increasing direct ownership by 4% to 123,082 units (SEC Form 4)

    4 - Elanco Animal Health Inc (0001739104) (Issuer)

    12/15/25 4:43:23 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elanco Animal Health upgraded by Piper Sandler

    Piper Sandler upgraded Elanco Animal Health from Neutral to Overweight

    1/22/26 8:20:23 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Elanco Animal Health with a new price target

    Barclays initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $30.00

    12/9/25 8:46:01 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KeyBanc Capital Markets initiated coverage on Elanco Animal Health with a new price target

    KeyBanc Capital Markets initiated coverage of Elanco Animal Health with a rating of Overweight and set a new price target of $27.00

    11/21/25 8:08:36 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Leadership Updates

    Live Leadership Updates

    View All

    Elanco executive appointed as Neurizon's Board Observer

    MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited ((ASX: NUZ &, NUZOA, OTCQB:NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health ("Elanco") (NYSE:ELAN) and will participate in Neurizon's Board activities as Elanco's designated representative. The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follo

    11/26/25 6:15:00 PM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600

    NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Elanco Animal Health Inc. (NYSE:ELAN) will replace Sarepta Therapeutics Inc. (NASD: SRPT) in the S&P MidCap 400, and Sarepta Therapeutics will replace Brookline Bancorp Inc. (NASD: BRKL) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, September 2. S&P SmallCap 600 constituent Berkshire Hills Bancorp Inc. (NYSE:BHLB) is acquiring Brookline Bancorp in a deal expected to be completed soon, pending final closing conditions. Post merger, Berkshire Hills Bancorp will remain in the S&P SmallCap 600 with a name and ticker change to Beacon Financial Corp. (NYSE:BBT). Following is a summary of the changes that will take place prior

    8/26/25 6:15:00 PM ET
    $BHLB
    $BRKL
    $ELAN
    Banks
    Finance
    Savings Institutions
    Biotechnology: Pharmaceutical Preparations

    Elanco Releases New Report Highlighting the Significance of America's Itchy Dogs and the Need for Itch Relief

    The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1Leading veterinarians and canine dermatologists, including Drs. Joya Griffin, Andrew Rosenberg, and Tom Lewis, are

    6/5/25 7:45:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/12/24 1:35:28 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    11/4/24 10:24:21 AM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by CarParts.com Inc.

    SC 13G/A - CarParts.com, Inc. (0001378950) (Subject)

    9/10/24 12:09:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    $ELAN
    $PRTS
    $TSPQ
    $KIN
    Financials

    Live finance-specific insights

    View All

    CarParts.com Reports Fourth Quarter and Fiscal Year 2025 Results

    LOS ANGELES, March 5, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS), a leading eCommerce provider of automotive parts and accessories, and a premier destination for vehicle repair and maintenance needs, is reporting results for the fourth quarter and fiscal year ended January 3, 2026.  Fiscal Year 2025 (53 weeks) Summary vs. Fiscal Year 2024 (52 weeks)Closed $35.7 million strategic investment from A-Premium, ZongTeng Group, and CDH Investments.Net sales decreased 7% to $547.5 million.Gross profit of $179.3 million vs. $196.7 million, with gross margin of 32.8%.Net loss w

    3/5/26 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary

    Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results

    Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day OutlookFourth Quarter 2025 Financial Results:Revenue of $1,144 million, increased 12% on a reported basis; 9% in organic constant currencyReported Net Loss of $276 million, Adjusted Net Income of $64 millionAdjusted EBITDA of $189 million; Adjusted EBITDA Margin of 16.7%Reported EPS of $(0.56), Adjusted EPS of $0.13Full Year 2025 Financial Results:Exceeded innovation revenue target at $892 million; delivered all 'Big 6' blockbuster potential products by the end of 2025 with Befrena approval in Q4 2025Revenue of $4,715 million, incre

    2/24/26 6:27:00 AM ET
    $ELAN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CarParts.com Sets Fourth Quarter 2025 Conference Call for Thursday, March 5, 2026

    LOS ANGELES, Feb. 12, 2026 /PRNewswire/ -- CarParts.com, Inc. (NASDAQ:PRTS) will hold a conference call on Thursday, March 5, 2026 at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss its financial results for the fourth quarter and fiscal year ended January 3, 2026. The results will be reported in a press release prior to the call. CarParts.com, Inc. CEO David Meniane and Interim CFO Mark DiSiena will host the conference call live via an audio webcast. The live webcast of the event can be accessed at www.carparts.com/investor/news-events. A replay of the webcast will

    2/12/26 4:01:00 PM ET
    $PRTS
    Auto & Home Supply Stores
    Consumer Discretionary